Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

Exclusion Criteria

• •Recurrent or metastatic HCC at enrollment.
• •Contraindication to peginterferon alfa-2b treatment.
• •WBC \< 3.5×10⁹/L or platelet count \< 100×10⁹/L.
• •ALT \> 3×ULN or total bilirubin (TBIL) \> 2×ULN.
• •Child-Pugh score \> 5 points.
• •INR \> 1.5.
• •History of organ transplantation or planned transplantation.
• •Hypersensitivity to peginterferon alfa-2b or any excipient of the study drug.
• •Pregnant or breastfeeding women.
• •Participation in another interventional clinical trial.
• •History of significant alcoholism or drug abuse.
• •Genetic or metabolic liver disease (Wilson disease, hemochromatosis, etc.).
• •Coinfection with HAV, HCV, HEV, EBV, CMV , or other viral hepatitis that may interfere with study evaluation.
• •Unable to comply with study procedures and follow-up.
• •Other conditions deemed inappropriate by the investigator.